Bioanalytical Method Development and Validation of Antihelmintic Drug in Human Plasma
DOI:
https://doi.org/10.22270/ajprd.v11i3.1414Abstract
Triclabendazole is an anthelmintic or anti-worm medication. Asimple and sensitive bio-analytical HPLC method with UV detection was developed and validated triclabendazole in human plasma. The analytes were extracted from human plasma samples by liquid-liquid extraction technique. Triclabendazole showed maximum absorbance i.e.; λmax at 305 nm. The developed analytical method was validated as per ICH guidelines. The chromatographic separation was achieved with Hypersil BDS C18 (250 mm x 4.6 mm, Particle size: 5 µm), software Autochrom 3000 using a mobile phase composition of acetonitrile and buffer (60:40 V/V) at a flow rate of 1.2 mL/min with a run time of 7 min.
The method showed good linearity in correlation coefficient (r) of >0.9998. The LOD and LOQ were found to be 1.00 µg mL-1 and 3.02 mg mL-1, respectively. Accuracy and precision data were found to be less than 2%, indicating the suitability of method. The developed HPLC method in human plasma using protein precipitation extraction for sample preparation was found to be very simple, reliable, precise, accurate, sensitive and selective analytical method for the estimation of Tricalbendazole. The method is suitable for routine quantitative analysis in pharmaceutical dosage forms. The method developed can be used in therapeutic drug monitoring units, bioequivalence and bioavailability studies, pharmacokinetic and toxicology studies of Tricalbendazole.
Downloads
References
International council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Guideline M10 on Bioanalytical Method Validation; 2019. p. 5-20.
Centr for Drug Evaluation and Research. Bioanalytical Method Validation Guidance for Industry, US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Bio pharmaceutics. Center for Drug Evaluation and Research; 2018. p. 5-11.
Sonawane LV. Bioanalytical method validation and its pharmaceutical application a review. Pharm Anal Acta 2014;5:2153-435.
Rajput D. Validation of analytical methods for pharmaceutical analysis. Int J Pharm Erud 2013;3:31-40.
US Food and Drug Administration. Drug Trials Snapshots: EGATEN. https://www.fda.gov/drugs/drug-trials-snapshots-egaten [accessed 29 April 2019].
K. D. Chatterjee, Parasitology, Protozoology and Helminthology, Guha Ray, Sree Saraswaty Press, Calcutta, India, 1967.
N. Mathew, S. Misra-Bhattacharya, V. Perumal, and K. Muthuswamy, “Antifilarial lead molecules isolated from Trachyspermum ammi,” Molecules, vol. 13, no. 9, pp. 2156–2168, 2008.
Mas-Coma S, Bargue MD, Valero MA. Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures. Parasitology. 2018145 (13 Special Issue):1665–1699
Mas-ComaS,BarguesMD,ValeroMA.Diagnosis of human fascioliasis by stool and blood techniques: update for the present global scenario. Parasitology. 2014141 (14):1918–1946.
Mas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Ad Parasitol. 2009; 6941–146.
Furst T, Keiser J, Utzinger J. Global burden of human food borne trematodiasis: a systematic review and metaanalysis. Lancet Infect Dis. 201212(3):210–221.Furst T, Keiser J, Utzinger J. Global burden of human food borne trematodiasis: a systematic review and metaanalysis. Lancet Infect Dis. 201212(3):210–221.
Lopez M, White AC Jr, Cabada MM. Burden of Fasciola hepatica infection amongchildrenfromPaucartamboinCusco,Peru.AmJTropMed Hyg. 2012;86(3):481–485.
Mas-Coma S, Argument VH, Valero MA. Neurological and ocular fascioliasis in humans. Adv Parasitol. 2014;84:27–149.
MillánJC,MullR,FreiseSetal.Theefficacyandtolerabilityof triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hy. 2000;63(5–6):264–269.
Arjona R, Riancho JA, Aguado JM et al. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore). 1995;74(1):13–23.
Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis. 200821(5):523–530.
Kaya M, Be¸sta¸s R, Cetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World J Gas troenterol. 2011;17(44):4899–4904.
Keiser J, Engels D, Büscher G et al. Triclabendazole for the treat ment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs. 2005;14(12):1513–1526.
GoralV,SenturkS,MeteOetal.AcaseofbiliaryFascioliasisbyFasciola gigantica in Turkey. Korean J Parasitol. 2011;49(1):65–68.
Hawramy TA, Saeed KA, Qaradaghy SH et al. Sporadic incidence of fascioliasis detected during hepatobiliary procedures: a study of 18 patients from Sulaimaniyah governorate. BMC Res Notes. 2012; 5:691
MusaD,Godbole G, Chiodini PL et al. Unusual case of a lung abscess. BMJ Case Rep 2013;2013: bcr2012008306. 18 Cabada MM, White AC Jr. New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis. 2012;25(5):518–522.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Pandey A. Sapna, Monika P. Jadhao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.